Blog

Sticker Shock

Author and Disclosure Information

 

A recent online study by Gerami et al in the Journal of the American Academy of Dermatology highlighted a new genomic method using messenger RNA to classify pigmented lesions as benign or malignant using a noninvasive adhesive patch developed by DermTech International. Patches were applied to the surface of pigmented lesions (42 melanomas; 22 nevi), vigorously rubbed, removed, frozen, and sent to the proprietary laboratory for RNA extraction and gene expression analysis. Then each lesion was excised for pathologic review. A 2-gene signature was discovered, including CMIP and LINC00518, differentiating melanoma from nevi with sensitivity of 97.6% and specificity of 72.7%.

What’s the issue?

Along with our evolving understanding and case-specific use of noninvasive modalities to diagnose difficult pigmented lesions, we add this test to the number of other tests and imaging approaches that seem perhaps too good to be true. A test that strips epithelial cells and involves no wound care but explores true gene differences likely sits better with us than surface microscopy, dermoscopy, and other imaging because, in this case, it provides a signature. A result. Similar to a pregnancy test, right? We wish. The diversity of pigmented lesions, especially the ones that stump us even on pathologic review, will likely prove too cryptic for 1 test to decode, but as these modalities evolve, their signatures will hopefully merge between researchers and industry to create a pigmented lesion map that we can all read. What noninvasive modalities do you use in your practices for pigmented lesions? How do you think this test will fit in?

We want to know your views! Tell us what you think.

Recommended Reading

Watch for the skin side effects of novel melanoma therapies
MDedge Dermatology
Evolving nanotechnology reveals potential treatment advantages
MDedge Dermatology
Is There a Potential Benefit of Expressive Writing for Dermatology Patients?
MDedge Dermatology
Teenage blistering sunburns increased melanoma risk by 80% in white women
MDedge Dermatology
FDA reclassifies tanning beds; warns against use by teens
MDedge Dermatology
High rate of durable responses to pembrolizumab in metastatic melanoma
MDedge Dermatology
‘Unprecedented’ overall survival of metastatic melanoma
MDedge Dermatology
VIDEO: Pembrolizumab may herald new hope in advanced melanoma
MDedge Dermatology
VIDEO: Advanced melanoma on brink of immunotherapy ‘revolution’
MDedge Dermatology
VIDEO: Drug combo delivers ‘unprecedented’ metastatic melanoma survival
MDedge Dermatology

Related Articles